Michele Esposito, MD
Advanced Heart Failure and Transplant Cardiology · Charleston, SCNPI 1568800373
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,300 of the $7,866 with a category attached, or 80.1%. Podimetrics, Inc. accounts for 80.1% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $6,591, more than ten times the $235 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in SC, where the typical reported total is $13,902.
Across 30 payments — averaging $262.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Podimetrics, Inc.$6K
- Abbott$268
- Abiomed$254
- Astellas Pharma US Inc$198
- Atricure, Inc.$192
- Medtronic$144
- plus $510 from 13 others
Across 2 payments — averaging $5054.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lantheus Medical Imaging, Inc.$10K
What the payments were for
- Consulting fees$6,30080%
- Food & beverage$1,22316%
- Education$3424%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Podimetrics, Inc. | 1 | $6,300 |
| Abbott | 2 | $268 |
| Abiomed | 2 | $254 |
| Astellas Pharma US Inc | 2 | $198 |
| Atricure, Inc. | 2 | $192 |
| Medtronic | 1 | $144 |
| Livanova USA, Inc. | 1 | $115 |
| Novartis | 4 | $68 |
| Johnson & Johnson | 2 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Boehringer Ingelheim | 2 | $41 |
| Amgen | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Pfizer | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Innovation Technologies Inc | 1 | $17 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,866 in reported general payments places this provider in the 30th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 14 | $10,351 |
| Metoprolol Succinate | 30 | $543 |
| Atorvastatin Calcium | 18 | $411 |
| Losartan Potassium | 23 | $227 |
| Lisinopril | 18 | $110 |
| Amlodipine Besylate | 19 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $68 | $10,35114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
Other advanced heart failure and transplant cardiology in Charleston
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Daniel JudgeCharleston$116K
- Ramsey WehbeCharleston$108K
- Sheldon LitwinCharleston$86K
- Brian HoustonCharleston$43K
- Jan GriffinCharleston$23K
- Adrian VanbakelCharleston$21K
- Daniel SilvermanCharleston$11K
- Vishal RaoCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.